November 2010 in “Clin-Alert” Monitoring for adverse effects in clinical treatments is crucial.
July 2016 in “Reactions Weekly” Cyproterone and finasteride reduced hypersexuality but caused serious side effects.
6 citations
,
February 2020 in “Journal of Natural Products” A new compound from a sponge strongly inhibits an enzyme linked to male-pattern hair loss without being toxic at low levels.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
147 citations
,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
January 2005 in “Fuzhou daxue xuebao. Ziran kexue ban” The method is quick and effective for testing steroid 5 alpha-reductase inhibitors.
3 citations
,
January 1996 in “Journal of Dermatological Treatment” The ointment is a safe, effective, and well-tolerated treatment for certain types of psoriasis.
10 citations
,
June 2010 in “Expert Opinion on Drug Metabolism & Toxicology” Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
1 citations
,
November 2025 in “International Journal of Clinical Pharmacy” Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
431 citations
,
October 2008 in “Current Medicinal Chemistry” Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.
January 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity” August 2011 in “SpringerReference”
14 citations
,
October 1977 in “The Lancet” November 2025 in “The Journal of Sexual Medicine” Using Mark Cuban Cost Plus Drug Company can save money on men's health medications compared to Medicare.
13 citations
,
January 2017 in “Chemical & Pharmaceutical Bulletin” Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
6 citations
,
April 2013 in “Journal of Investigative Dermatology” Spironolactone might lower the chance of getting rosacea.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
78 citations
,
October 2003 in “Cochrane library” Cyproterone acetate with estradiol may subjectively improve excessive hair growth in women, but it's not clinically better than other treatments.
8 citations
,
October 1998 in “Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology” Proscar (finasteride) blocks 5α-reductase in sea urchin ovaries and testes, suggesting potential treatment for androgen-related conditions.
8 citations
,
November 2010 in “British journal of dermatology/British journal of dermatology, Supplement” Vitamin D protects skin cells from damage caused by captopril.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
June 2026 in “Preprints.org” Atorvastatin in a keratin hydrogel may help treat skin scars effectively.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
November 2005 in “The Journal of Urology” 5 citations
,
January 1991 in “Drugs of The Future” 87 citations
,
January 1996 in “Journal of cellular biochemistry” Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.